Enanta Pharmaceuticals, Inc.
ENTA
$13.85
$0.010.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 23.07% | -17.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.07% | -17.41% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 23.07% | -17.41% | |||
| SG&A Expenses | -7.14% | -2.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.87% | -9.93% | |||
| Operating Income | 38.80% | 2.68% | |||
| Income Before Tax | 36.18% | -2.43% | |||
| Income Tax Expenses | -25.00% | 10.34% | |||
| Earnings from Continuing Operations | 36.16% | -2.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.16% | -2.44% | |||
| EBIT | 38.80% | 2.68% | |||
| EBITDA | 41.39% | 3.29% | |||
| EPS Basic | 52.52% | -2.41% | |||
| Normalized Basic EPS | 54.92% | -7.66% | |||
| EPS Diluted | 52.52% | -2.41% | |||
| Normalized Diluted EPS | 54.92% | -7.66% | |||
| Average Basic Shares Outstanding | 34.46% | 0.01% | |||
| Average Diluted Shares Outstanding | 34.46% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||